Comparison of efficacy, advantages and side effects of Tislelizumab

Tislelizumab (Tislelizumab) is a humanized anti-PD-1 monoclonal antibody drug independently developed by BeiGene (BeiGene). It is one of the first immune checkpoint inhibitors approved for marketing in China. Since its first approval in 2019, tislelizumab has been extensively used in clinical research and application in a variety of malignant tumors, with indications covering non-small cell lung cancer, liver cancer, esophageal cancer, nasopharyngeal cancer and other fields. This article will comprehensively analyze the performance of tislelizumab in immunotherapy from two aspects: efficacy advantages and side effects.

1. The efficacy and advantages of tislelizumab

1.Precise design: avoid FcγR binding and reduce the risk of immune-related toxicity

Tislelizumab has been structurally optimized, and its Fc segment has been engineered to eliminate the ability to bind to the Fcγ receptor (FcγR). This design reduces antibody-dependent phagocytosis (ADCP), thereby reducing the possibility that the drug may cause the immune system to attack its own T cells, while retaining anti-tumor efficacy while reducing certain toxic reactions.

2.The efficacy is significant, and the results of many studies are positive

In the field of non-small cell lung cancer (NSCLC), tislelizumab has demonstrated excellent efficacy in multiple Phase III clinical studies. For example, in the RATIONALE 307 study, tislelizumab combined with chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) compared with chemotherapy alone. In the esophageal cancer study (RATIONALE 302), tislelizumab significantly prolonged overall survival in second-line treatment and was superior to control regimens such as docetaxel.

3. Covering a wide range of indications, combination therapy has broad prospects

In addition to lung cancer and esophageal cancer, tislelizumab has also made positive progress in various solid tumors such as hepatocellular carcinoma, nasopharyngeal cancer, bladder cancer, and renal cancer, and the number of indications has continued to expand. In addition, its combined application strategies with chemotherapy, targeted therapy, radiotherapy and other methods are constantly optimized, which is expected to further improve the efficacy and break through the bottleneck of immune resistance.

4. Strong domestic accessibility and high cost performance

Tislelizumab, as a domestic innovative drug, has been included in China’s national medical insurance catalog. Its price is compared with imported PD-1 antibodies such as nivolumab (Nivolumab) and pembrolizumab (Pembrolizumab) are more user-friendly, allowing more patients to receive long-term and continuous immunotherapy, further promoting the widespread application of immunotherapy among Chinese cancer patients.

2. Side effects and countermeasures of tislelizumab

Although tislelizumab has considerable efficacy, as an immune checkpoint inhibitor, its side effects mainly come from the "overactivation" of the immune system, leading to immune-related adverse events (irAEs), which is also a common problem faced by all PD-1 drugs.

1.Common side effects

The most common adverse reactions of tislelizumab include fatigue, rash, fever, loss of appetite, etc., generally ranging from 1 to 2 mild to moderate reactions, which can be relieved by symptomatic and supportive treatment and will not affect the continuity of treatment. Skin reactions such as rash and itching are common, but most can be relieved by topical steroids or antihistamines.

2.Immune-related adverse events (irAEs)

Tislelizumab may cause pneumonia, hepatitis, thyroid dysfunction, colitis, etc.irAEs, which are mainly caused by the increased activity of T cells that attack their own tissues. For example, immune-related pneumonia may present with cough and shortness of breath, and in severe cases, medication may need to be suspended and systemic hormone therapy may be used. Immune hepatitis manifests as elevated ALT/AST, and liver function also needs to be monitored and treated in a timely manner.

3. Management and monitoring suggestions

Before tislelizumab treatment, patients should be systematically evaluated, including basic organ function, previous history of autoimmune diseases, etc.; during treatment, blood routine, liver and kidney function, thyroid function and lung imaging should be regularly monitored to facilitate early identification of side effects. Once it appears3For toxic reactions of grade 1 or above, treatment should be suspended immediately and hormonal intervention initiated according to the guidelines.

4.Safety compared with otherPD-1 drugs

Clinical data show that the incidence of immune-related side effects of tislelizumab is comparable to other PD-1 monoclonal antibodies, but its structural optimization may make it less toxic, such as immune cell attack, and therefore better tolerated in specific patients. In addition, its lower price reduces the financial burden of interrupting treatment due to side effects and provides patients with protection for continued medication.

3. Conclusion

Overall, tislelizumab, as an innovative immunotherapy drug developed locally in China, has demonstrated significant advantages in terms of efficacy, safety, indication expansion and economy. It not only fills the gap in the domestic anti-PD-1 field, but also brings more new options with high accessibility and accurate efficacy to Chinese cancer patients. Although immune-related side effects are still a matter of great clinical concern, as long as they are scientifically evaluated and managed, most patients can benefit safely and long-term. With the introduction of more combination treatment options, tislelizumab is expected to occupy a more important position in the field of tumor treatment in the future.

Reference materials:https://www.drugs.com